Literature DB >> 25341748

Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.

Danique L M van Broekhoven1, Cornelis Verhoef, Dirk J Grünhagen, Joost M H H van Gorp, Michael A den Bakker, John W J Hinrichs, Carmen M A de Voijs, Thijs van Dalen.   

Abstract

BACKGROUND: Aggressive fibromatosis (AF) comprises tumors with a varying biological behavior. Genetic tumor characteristics may be predictive of recurrence; hence, the prognostic value of three specific mutations on the CTNNB1 gene was evaluated in relation to known clinicopathologic risk factors in patients with primary, sporadic AF.
METHODS: In a multi-institutional retrospective cohort study of patients with primary extra-abdominal and abdominal wall AF who underwent surgical treatment, the original pathology specimens were reviewed for the presence of a T41A, S45F, and 45P mutations on the CTNNB1 gene. For these mutations, the risk of recurrence was analyzed by the Kaplan-Meier method with log-rank test. Univariable and multivariable Cox regression was performed to calculate hazard ratios.
RESULTS: A total of 101 patients were analyzed. During a median follow-up of 41 months, 17 recurrences were detected; the cumulative 5-year recurrence rate was 22.8 %. A specific CTNNB1 mutation was found in 76 patients, with the majority of patients having a T41A mutation (n = 49). CTNNB1 mutations were associated with the risk of recurrence: the presence of a S45F mutation was associated with a 5-year cumulative risk of recurrence of 63.8 % (P < 0.001). Multivariable analysis showed that young age and S45F mutation were independent risk factors (P = 0.011 and P < 0.001).
CONCLUSIONS: The presence of specific CTNNB1 mutations was predictive for recurrence in patients after surgical treatment for primary, sporadic extra-abdominal and abdominal AF. A S45F mutation increased the risk of recurrence significantly.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25341748     DOI: 10.1245/s10434-014-4156-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.

Authors:  Xin Liu; Huijie Wang; Xianghua Wu; Xiaonan Hong; Zhiguo Luo
Journal:  Invest New Drugs       Date:  2017-11-23       Impact factor: 3.850

2.  Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroshi Urakawa; Shunsuke Hamada; Eiji Kozawa; Kunihiro Ikuta; Yuichi Ando; Naoki Ishiguro
Journal:  Int J Clin Oncol       Date:  2015-04-22       Impact factor: 3.402

Review 3.  The Landmark Series: Desmoid.

Authors:  Marco Fiore; Aimee Crago; Rebecca Gladdy; Bernd Kasper
Journal:  Ann Surg Oncol       Date:  2021-01-01       Impact factor: 5.344

4.  Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.

Authors:  Danielle Braggio; David Koller; Feng Jin; Nanda Siva; Abeba Zewdu; Gonzalo Lopez; Kara Batte; Lucia Casadei; Meng Welliver; Anne M Strohecker; Dina Lev; Raphael E Pollock
Journal:  Cancer       Date:  2019-04-12       Impact factor: 6.860

5.  Squamous cell carcinoma of the lung with highly proliferating fibromatosis-like stroma: a rare phenomenon.

Authors:  Shogo Tajima; Yusuke Takanashi; Kenji Koda
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors.

Authors:  David P Douglass; Fariba Navid; Aaron R Weiss
Journal:  Paediatr Drugs       Date:  2022-07-29       Impact factor: 3.930

Review 7.  Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis.

Authors:  Francesco Prete; MariaTeresa Rotelli; Alessandro Stella; Giovanna Calculli; Lucia Ilaria Sgaramella; Antonio Amati; Nicoletta Resta; Mario Testini; Angela Gurrado
Journal:  Clin Exp Med       Date:  2022-08-01       Impact factor: 5.057

8.  Peutz-Jeghers syndrome with mesenteric fibromatosis: A case report and review of literature.

Authors:  Huai-Jie Cai; Han Wang; Nan Cao; Wei Wang; Xi-Xi Sun; Bin Huang
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

9.  Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesions.

Authors:  Jérôme Doyen; Valérie Duranton-Tanneur; Isabelle Hostein; Marie Karanian-Philippe; Christine Chevreau; Florence Breibach; Michael Coutts; Bérengère Dadone; Marie-Christine Saint-Paul; Jean Gugenheim; Florence Duffaud; Florence Pedeutour
Journal:  Virchows Arch       Date:  2015-12-14       Impact factor: 4.064

10.  Characteristics of cultured desmoid cells with different CTNNB1 mutation status.

Authors:  Shunsuke Hamada; Hiroshi Urakawa; Eiji Kozawa; Eisuke Arai; Kunihiro Ikuta; Tomohisa Sakai; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Cancer Med       Date:  2015-12-21       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.